Paulus Kirchhof

Aug 25, 2023 | healio.com | Erik Swain |Richard Smith |Paulus Kirchhof

Source/Disclosures Source: Kirchhof P, et al. Hot line 1. Presented at: European Society of Cardiology Congress; Aug. 25-28, 2023; Amsterdam (hybrid meeting). Disclosures: The study was funded in part by Daiichi Sankyo Europe. Kirchhof reports serving as speaker of the board for AFNET, which received research grants from various drug and device companies, receiving research grants from Daiichi Sankyo and holding two patents issued in the EU related to AF diagnosis and therapy.

Aug 25, 2023 | aerjournal.com | Paulus Kirchhof |Robert Byrne

ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577).

Jun 1, 2023 | learn.acc.org | Suneet Mittal |Stefan H. Hohnloser |Paulus Kirchhof |Jonathan P. Piccini

We are grateful to these distinguished faculty who contributed to this collection:

Mar 29, 2023 | healio.com | Erik Swain |Richard Smith |Paulus Kirchhof

Source/Disclosures Disclosures: Gottschalk reports no relevant financial disclosures. Kirchhof reports receiving research support for basic, translational and clinical research projects from several drug and device companies active in atrial fibrillation and receiving honoraria from several such companies in the past, but not in the last 3 years, and being listed as inventor on two patents held by the University of Birmingham.